Description:
MK-8353 is an orally available ERK1/2 inhibitor. It exhibited antitumor activity in patients with BRAFV600-mutant melanoma.
- Molecular Weight: 691.84
- Molecular Formula: C37H41N9O3S
Canonical SMILES:
CC(C)OC1=NC=C(C=C1)C2=NNC3=C2C=C(C=C3)NC(=O)C4(CCN(C4)CC(=O)N5CCC(=CC5)C6=CC=C(C=C6)C7=NN(C=N7)C)SC
InChI:
InChI=1S/C37H41N9O3S/c1-24(2)49-32-12-9-28(20-38-32)34-30-19-29(10-11-31(30)41-42-34)40-36(48)37(50-4)15-18-45(22-37)21-33(47)46-16-13-26(14-17-46)25-5-7-27(8-6-25)35-39-23-44(3)43-35/h5-13,19-20,23-24H,14-18,21-22H2,1-4H3,(H,40,48)(H,41,42)/t37-/m0/s1
InChIKey: KPQQGHGDBBJGFA-QNGWXLTQSA-NSynonyms:
(3S)-3-(methylthio)-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxy-3-pyridinyl)-1H-indazol-5-yl]-3-pyrrolidinecarboxamide
More details are to be found on supplier website
